← Back to Search

Other

Deucrictibant for Hereditary Angioedema (RAPIDe-1 Trial)

Phase 2
Waitlist Available
Led By Marcus Maurer, Prof MD
Research Sponsored by Pharvaris Netherlands B.V.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 hours post-treatment
Awards & highlights

RAPIDe-1 Trial Summary

This study is evaluating whether a drug can reduce the severity of attacks in people with hereditary angioedema.

Eligible Conditions
  • Hereditary Angioedema
  • C1 Esterase Inhibitor Deficiency

RAPIDe-1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 hours post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 hours post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change of the 3-symptom composite visual analogue scale (VAS-3) score from pre-treatment to 4 hours post-treatment
Secondary outcome measures
Mean symptom complex severity (MSCS) score
Proportion of study drug treated attacks requiring HAE rescue medication
Time to onset of almost complete and complete symptom relief by visual analogue scale (VAS-3)
+6 more

RAPIDe-1 Trial Design

3Treatment groups
Experimental Treatment
Group I: Medium dose/placeboExperimental Treatment2 Interventions
Single medium dose of deucrictibant or placebo
Group II: Low dose/placeboExperimental Treatment2 Interventions
Single low dose of deucrictibant or placebo
Group III: High dose/placeboExperimental Treatment2 Interventions
Single high dose of deucrictibant or placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucrictibant
2021
Completed Phase 2
~80
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

Pharvaris Netherlands B.V.Lead Sponsor
4 Previous Clinical Trials
252 Total Patients Enrolled
Marcus Maurer, Prof MDPrincipal InvestigatorCharite University, Berlin, Germany
1 Previous Clinical Trials
72 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
2021. "Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04618211.
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top